September 29, 2020
EAASM Report on Patient Safety and Nanomedicines Calls for Centralized Regulatory Procedure
On September 17, 2020, the European Alliance for Access to Safe Medicines (EAASM) announced the availability of a report entitled Patient Safety and Nanomedicines: The need for a centralised regulatory procedure. According to EAASM, “[n]anomedicines and their follow-on products, also referred to as nanosimilars, are complex molecules and so regulatory oversight must be scientifically fit for purpose.” The report makes three key recommendations intended to...